Providing market intelligence for more than 35 years

In The News

More than 278 million viewers will watch subscription ad-supported streaming services by 2029 – Parks Associates

Parks Associates' new white paper, Interactive & Shoppable TV: Next Wave of CTV Revenues, released in partnership with Adeia, focuses on the service provider opportunity to advance the consumer experience and build on expectations of interactivity and specifically engage in commerce through the TV. Parks Associates forecasts that by 2029, more than 278 million viewers will watch subscription ad-supported streaming and that consumers are open to expanded commercial experiences on the TV.

The white paper highlights consumer interest, use, and preferences for interactive features across TV and mobile viewing devices and platforms, including shoppable advertisements.

From the LightReading article, "More than 278 million viewers will watch subscription ad-supported streaming services by 2029 – Parks Associates"

Previously In The News

Samsung Leads in 4K TV Sales, Report Shows

Parks reported that 19 percent of U.S. broadband households intend to purchase a flat-panel TV set by the end of 2015. Roughly 40 percent of those households are looking for a 4K TV set, which is appr...

Cord Cutters Face A Sea Of Streaming Options

Hartstein’s decision was made easier because of a flood of Internet streaming services that allows consumers to cobble together their own video packages. There are more than 100 Internet video service...

Over Two-Thirds Of U.S. Smartphone Owners Stream Music Daily

A recent Parks Associates report reveals that 68 percent of U.S. smartphone owners listen to streaming music every day, for an average of 45 minutes per day. Amazon Prime Music emerged as the most pop...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...